Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Common Equity (2022 - 2025)

Praxis Precision Medicines (PRAX) has 4 years of Common Equity data on record, last reported at $878.1 million in Q4 2025.

  • For Q4 2025, Common Equity rose 97.13% year-over-year to $878.1 million; the TTM value through Dec 2025 reached $878.1 million, up 97.13%, while the annual FY2025 figure was $878.1 million, 97.13% up from the prior year.
  • Common Equity reached $878.1 million in Q4 2025 per PRAX's latest filing, up from $343.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $878.1 million in Q4 2025 and bottomed at $64.5 million in Q1 2023.
  • Average Common Equity over 4 years is $273.7 million, with a median of $210.4 million recorded in 2022.
  • Peak YoY movement for Common Equity: tumbled 66.25% in 2023, then surged 539.38% in 2024.
  • A 4-year view of Common Equity shows it stood at $76.1 million in 2022, then fell by 8.46% to $69.7 million in 2023, then soared by 539.38% to $445.4 million in 2024, then surged by 97.13% to $878.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $878.1 million in Q4 2025, $343.5 million in Q3 2025, and $404.2 million in Q2 2025.